Kinetic analysis of 18F-fluorodihydrorotenone as a deposited myocardial flow tracer: comparison to 201Tl. Read more about Kinetic analysis of 18F-fluorodihydrorotenone as a deposited myocardial flow tracer: comparison to 201Tl.
Exemption of radiopharmaceuticals from <797>. Read more about Exemption of radiopharmaceuticals from .
Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. Read more about Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a.
Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. Read more about Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.
Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members. Read more about Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members.
Kinetic analysis of 125I-iodorotenone as a deposited myocardial flow tracer: comparison with 99mTc-sestamibi. Read more about Kinetic analysis of 125I-iodorotenone as a deposited myocardial flow tracer: comparison with 99mTc-sestamibi.
Neuroblastoma imaging using a combined CT scanner-scintillation camera and 131I-MIBG. Read more about Neuroblastoma imaging using a combined CT scanner-scintillation camera and 131I-MIBG.
Diagnostic accuracy of 99mTc-sestamibi breast imaging: multicenter trial results. Read more about Diagnostic accuracy of 99mTc-sestamibi breast imaging: multicenter trial results.
Treatment of SW620 cells with Tomudex and oxaliplatin induces changes in 2-deoxy-D-glucose incorporation associated with modifications in glucose transport. Read more about Treatment of SW620 cells with Tomudex and oxaliplatin induces changes in 2-deoxy-D-glucose incorporation associated with modifications in glucose transport.
A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. Read more about A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.
